Email Alert RSS
Volume 12 Issue 2
May  2021
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Gynecological Oncology Society of Chinese Medical Association, Chinese Society for Colposcopy and Cervical Pathology. Chinese Expert Consensus on Clinical Application of Human Papilloma Virus Vaccine[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 189-201. DOI: 10.12290/xhyxzz.2021-0082
Citation: Gynecological Oncology Society of Chinese Medical Association, Chinese Society for Colposcopy and Cervical Pathology. Chinese Expert Consensus on Clinical Application of Human Papilloma Virus Vaccine[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 189-201. DOI: 10.12290/xhyxzz.2021-0082
shu

Chinese Expert Consensus on Clinical Application of Human Papilloma Virus Vaccine

  • 1.

    Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China

  • 2.

    Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China

  • 3.

    Women's Hopital, School of Medicine Zhejiang University, Hangzhou 310006, China, E-mail: xiex@ zju.edu.cn

  • 4.

    Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, China

More Information
  • Received Date: January 21, 2021
  • Accepted Date: January 21, 2021
  • Available Online: January 31, 2021
  • Issue Publish Date: May 29, 2021
    Graphical Abstract
    • Abstract
  • Human papilloma virus (HPV) vaccination is a primary preventive measure and an effective method to prevent HPV infection and the related diseases. Its effect in young women is better, and the immune efficacy of vaccination for teenagers before sexual exposure is the best. HPV vaccine is not only suitable for the general population, but also recommended for high-risk and special groups. HPV vaccination should be recommended for women at the appropriate age with genetic susceptibility, high-risk lifestyle, or HIV infection. No matter whether they have HPV infection or abnormal cytology, women of appropriate ages can be vaccinated. Women with a pregnancy plan in the near future and pregnant or lactating women should not be vaccinated. Recommendation of cervical cancer screening should be carried out after HPV vaccination.
    • FullText(HTML)
    • References (92)
  • [1]
    McBride AA. Oncogenic human papillomaviruses[J]. Philos Trans R Soc Lond B Biol Sci, 2017, 372: 20160273. DOI: 10.1098/rstb.2016.0273
    [2]
    Chesson HW, Dunne EF, Hariri S, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States[J]. Sex Transm Dis, 2014, 41: 660-664. DOI: 10.1097/OLQ.0000000000000193
    [3]
    Gargano J, Meites E, Watson M, et al. Manual for the Surveillance of Vaccine-Preventable Diseases: Human Papillomavirus[EB/OL]. (2020-04-28)[2020-11-28]. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt05-hpv.html.
    [4]
    World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations[J]. Vaccine, 2017, 35: 5753-5755. DOI: 10.1016/j.vaccine.2017.05.069
    [5]
    Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings[J]. J Infect Dis, 2010, 202: 1789-1799. DOI: 10.1086/657321
    [6]
    Guan P, Howell-Jones R, Li N, et al. Human papillo-mavirus types in 115, 789 HPV-positive women: a meta-analysis from cervical infection to cancer[J]. Int J Cancer, 2012, 131: 2349-2359. DOI: 10.1002/ijc.27485
    [7]
    World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017[J]. Wkly Epidemiol Rec, 2017, 92: 241-268. http://www.ncbi.nlm.nih.gov/pubmed/28596091
    [8]
    de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. Lancet Oncol, 2010, 11: 1048-1056. DOI: 10.1016/S1470-2045(10)70230-8
    [9]
    Wu EQ, Liu B, Cui JF, et al. Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study[J]. Cancer Causes Control, 2013, 24: 795-803. DOI: 10.1007/s10552-013-0162-8
    [10]
    Chen W, Zhang X, Molijn A, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18[J]. Cancer Causes Control, 2009, 20: 1705-1713. DOI: 10.1007/s10552-009-9422-z
    [11]
    de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8: e180-e190. DOI: 10.1016/S2214-109X(19)30488-7
    [12]
    de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type[J]. Int J Cancer, 2017, 141: 664-670. DOI: 10.1002/ijc.30716
    [13]
    Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World[R/OL]. (2019-06-17)[2020-11-25]. https://hpvcentre.net/statistics/reports/XWX.pdf?t=1606721151283.
    [14]
    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424. DOI: 10.3322/caac.21492
    [15]
    Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in China[R/OL]. (2019-06-17)[2020-11-25]. https://hpvcentre.net/statistics/reports/CHN.pdf?t=1606722464904.
    [16]
    Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap: differences in human papill-omavirus infection natural history, transmission and human papill-omavirus-related cancer incidence by gender and anatomic site of infection[J]. Int J Cancer, 2015, 136: 2752-2760. DOI: 10.1002/ijc.29082
    [17]
    Centers for Disease Control and Prevertion. Human Papill-omavirus (HPV) Infection[EB/OL]. (2015-06-04)[2020-11-25]. https://www.cdc.gov/std/tg2015/hpv.htm.
    [18]
    Colombara DV, Wang SM. The impact of HPV vaccin-ation delays in China: lessons from HBV control programs[J]. Vaccine, 2013, 31: 4057-4059. DOI: 10.1016/j.vaccine.2013.06.031
    [19]
    Zeng ZY, Yang HT, Li ZB, et al. Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51, 345 HPV Genotyping Results from China's Largest CAP Certified Laboratory[J]. J Cancer, 2016, 7: 1037-1043. DOI: 10.7150/jca.14971
    [20]
    Wei LH, Xie X, Liu JH, et al. Efficacy of quadrivalent human papill-omavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up[J]. Vaccine, 2019, 37: 3617-3624. DOI: 10.1016/j.vaccine.2018.08.009
    [21]
    Zhu FC, Li J, Hu YM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years[J]. Hum VaccinImmunother, 2014, 10: 1795-1806. DOI: 10.4161/hv.28702
    [22]
    Li RC, Li YP, Radley D, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females[J]. Vaccine, 2012, 30: 4284-4291. DOI: 10.1016/j.vaccine.2012.02.079
    [23]
    Hu YM, Guo M, Li CG, et al. Immunogenicity nonin-feriority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women[J]. Sci China Life Sci, 2020, 63: 582-591. DOI: 10.1007/s11427-019-9547-7
    [24]
    Van Damme P, Meijer CJLM, Kieninger D, et al. A phase Ⅲ clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men[J]. Vaccine, 2016, 34: 4205-4212. DOI: 10.1016/j.vaccine.2016.06.056
    [25]
    Joura EA, Kyrgiou M, Bosch FX, et al. Human papillo-mavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy[J]. Eur J Cancer, 2019, 116: 21-26. DOI: 10.1016/j.ejca.2019.04.032
    [26]
    Barr E, Gause CK, Bautista OM, et al. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women[J]. Am J Obstet Gynecol, 2008, 198: 261. e1-e11. DOI: 10.1016/j.ajog.2007.09.001
    [27]
    Australian Government Department of Health. Human papillomavirus (HPV) immunization service[EB/OL]. (2019-09-26)[2020-11-25]. https://www.health.gov.au/health-topics/immunisation/immunisation-services/human-papillomavirus-hpv-immunisation.
    [28]
    Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection[J]. Hum Vaccin, 2009, 5: 696-704. DOI: 10.4161/hv.5.10.9515
    [29]
    Zhu FC, Hu SY, Hong Y, et al. Efficacy, immuno-genicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase Ⅱ/Ⅲ, rando-mised, controlled trial[J]. Cancer Med, 2019, 8: 6195-6211. DOI: 10.1002/cam4.2399
    [30]
    Qiao YL, Wu T, Li RC, et al. Efficacy, Safety, and Immuno-genicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial[J]. J Natl Cancer Inst, 2020, 112: 145-153. DOI: 10.1093/jnci/djz074
    [31]
    Future Ⅱ Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions[J]. N Engl J Med, 2007, 356: 1915-1927. DOI: 10.1056/NEJMoa061741
    [32]
    Lei JY, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer[J]. N Engl J Med, 2020, 383: 1340-1348. DOI: 10.1056/NEJMoa1917338
    [33]
    Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J]. N Engl J Med, 2015, 372: 711-723. DOI: 10.1056/NEJMoa1405044
    [34]
    Garland SM, Pitisuttithum P, Ngan HYS, et al. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries[J]. J Infect Dis, 2018, 218: 95-108. DOI: 10.1093/infdis/jiy133
    [35]
    Ruiz-Sternberg ÁM, Moreira ED Jr, Restrepo JA, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women[J]. Papillomavirus Res, 2018, 5: 63-74. DOI: 10.1016/j.pvr.2017.12.004
    [36]
    International Federation of Gynecology & Obstetrics. Global Guidance For Cervical Cancer Prevention and Control (2009)[EB/OL]. [2020-11-25]. https://www.figo.org/sites/default/files/2020-07/Control_English_version.pdf.
    [37]
    中华预防医学会疫苗与免疫分会. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识(简版)[J]. 中华预防医学杂志, 2019, 53: 1218-1235. DOI: 10.3760/cma.j.issn.0253-9624.2019.12.006
    [38]
    U.S. Food & Drug Administration. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old[EB/OL]. (2018-10-05)[2020-11-25]. https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old.
    [39]
    Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Morb Mortal Wkly Rep, 2019, 68: 698-702. DOI: 10.15585/mmwr.mm6832a3
    [40]
    Centers for Disease Control and Prevertion. Vaccines at 11 to 12 Years[EB/OL]. (2020-02-25)[2020-11-25]. https://www.cdc.gov/vaccines/parents/by-age/years-11-12.html.
    [41]
    Immunization Expert Work Group, Committee on Adolescent Health Care. Committee Opinion No. 704: Human Papillo-mavirusVaccination[J]. Obstet Gynecol, 2017, 129: 1. DOI: 10.1097/AOG.0000000000002052
    [42]
    Government of Canada. Human papillomavirus vaccine: Canadian Immunization Guide[EB/OL]. [2020-11-25]. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html.
    [43]
    Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation[J]. CA Cancer J Clin, 2020, 70: 274-280. DOI: 10.3322/caac.21616
    [44]
    Zhao FH, Tiggelaar SM, Hu SY, et al. A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vacci-nation in China[J]. Cancer Epidemiol, 2012, 36: 384-390. DOI: 10.1016/j.canep.2012.01.009
    [45]
    Li K, Li Q, Song L, et al. The distribution and prevalence of human papillomavirus in women in mainland China[J]. Cancer, 2019, 125: 1030-1037. DOI: 10.1002/cncr.32003
    [46]
    Zhao FH, Lewkowitz AK, Hu SY, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies[J]. Int J Cancer, 2012, 131: 2929-2938. DOI: 10.1002/ijc.27571
    [47]
    Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreac-tivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica[J]. Cancer Epidemiol Biomarkers Prev, 2004, 13: 324-327. DOI: 10.1158/1055-9965.EPI-03-0166
    [48]
    Castellsagué X, Muñoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age[J]. Br J Cancer, 2011, 105: 28-37. DOI: 10.1038/bjc.2011.185
    [49]
    Giuliano AR, Joura EA, Garland SM, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo popul-ation[J]. Gynecol Oncol, 2019, 154: 110-117. http://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsRW5nTmV3UzIwMjEwMzAyEiA3ZjA3MzY2MDI1YzU4MTUxMWRlYTE3MGYyZjczOTllNRoIZXlqamw2bGM%3D
    [50]
    Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial[J]. Lancet, 2017, 390: 2143-2159. DOI: 10.1016/S0140-6736(17)31821-4
    [51]
    Panagiotou OA, Befano BL, Gonzalez P, et al. Effectof bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial[J]. BMJ, 2015, 351: h4358. http://smartsearch.nstl.gov.cn/paper_detail.html?id=f6423ef439caab48ed04eeb0a03b2b30
    [52]
    Angelo MG, Zima J, Tavares Da Silva F, et al. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience[J]. Pharmacoepidemiol Drug Saf, 2014, 23: 456-465. DOI: 10.1002/pds.3593
    [53]
    Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Morb Mortal Wkly Rep, 2010, 59: 626-629. http://www.cabdirect.org/abstracts/20103180825.html
    [54]
    Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papilloma virus type 6/11/16/18 vaccine: a combined analysis of five random-ized controlled trials[J]. Obstet Gynecol, 2009, 114: 1179-1188. DOI: 10.1097/AOG.0b013e3181c2ca21
    [55]
    Scheller NM, Pasternak B, Mølgaard-Nielsen D, et al. Quadrivalent HPV Vaccination and the Risk of Adverse Pregn-ancyOutcomes[J]. N Engl J Med, 2017, 376: 1223-1233. DOI: 10.1056/NEJMoa1612296
    [56]
    Landazabal CS, Moro PL, Lewis P, et al. Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017[J]. Vaccine, 2019, 37: 1229-1234. DOI: 10.1016/j.vaccine.2018.11.077
    [57]
    Tan J, Xiong YQ, He Q, et al. Peri-conceptional or pregnancy exposure of HPV vaccination and the risk of sponta-neous abortion: a systematic review and meta-analysis[J]. BMC Pregnancy Childbirth, 2019, 19: 302. DOI: 10.1186/s12884-019-2425-1
    [58]
    Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Recomm Rep, 2014, 63: 1-30.
    [59]
    Min KJ, Kwon SH, Kim K, et al. Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Onco-logy Guideline[J]. J Gynecol Oncol, 2019, 30: e31. DOI: 10.3802/jgo.2019.30.e31
    [60]
    Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?[J]. Gynecol Oncol, 2013, 130: 264-268. DOI: 10.1016/j.ygyno.2013.04.050
    [61]
    Garland SM, Paavonen J, Jaisamrarn U, et al. Prior human papillomavirus-16/18 AS04-adjuvanted vaccin-ation prevents recurrent high grade cervical intraep-ithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial[J]. Int J Cancer, 2016, 139: 2812-2826. DOI: 10.1002/ijc.30391
    [62]
    Ghelardi A, Parazzini F, Martella F, et al. SPERANZA project: HPV vaccination after treatment for CIN2[J]. Gynecol Oncol, 2018, 151: 229-234. DOI: 10.1016/j.ygyno.2018.08.033
    [63]
    Pieralli A, Bianchi C, Auzzi N, et al. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease[J]. Arch Gynecol Obstet, 2018, 298: 1205-1210. DOI: 10.1007/s00404-018-4926-y
    [64]
    Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study[J]. Clin Infect Dis, 2012, 54: 891-898. DOI: 10.1093/cid/cir1036
    [65]
    Deshmukh AA, Chhatwal J, Chiao EY, et al. Long-Term Outcomes of Adding HPV Vaccine to the Anal Intrae-pithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men[J]. Clin Infect Dis, 2015, 61: 1527-1535. DOI: 10.1093/cid/civ628
    [66]
    Markowitz LE, Dunne EF, Saraiya M, et al. Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP)[EB/OL]. (2014-08-29)[2020-11-25]. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6305a1.htm.
    [67]
    Hemminki K, Dong C, Vaittinen P. Familial risks in cervical cancer: is there a hereditary component?[J]. Int J Cancer, 1999, 82: 775-781. DOI: 10.1002/(SICI)1097-0215(19990909)82:6<775::AID-IJC1>3.0.CO;2-V
    [68]
    Magnusson PK, Lichtenstein P, Gyllensten UB. Heritability of cervical tumours[J]. Int J Cancer, 2000, 88: 698-701. DOI: 10.1002/1097-0215(20001201)88:5<698::AID-IJC3>3.0.CO;2-J
    [69]
    Chen D, Juko-Pecirep I, Hammer J, et al. Genome-wide association study of susceptibility loci for cervical cancer[J]. J Natl Cancer Inst, 2013, 105: 624-633. DOI: 10.1093/jnci/djt051
    [70]
    Shi YY, Li L, Hu ZB, et al. A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12[J]. Nat Genet, 2013, 45: 918-922. DOI: 10.1038/ng.2687
    [71]
    Tovar JM, Bazaldua OV, Vargas L, et al. Human papillomavirus, cervical cancer, and the vaccines[J]. Postgrad Med, 2008, 120: 79-84. DOI: 10.3810/pgm.2008.07.1794
    [72]
    Moscicki AB. Impact of HPV infection in adolescent populations[J]. J Adolesc Health, 2005, 37: S3-S9. http://www.ncbi.nlm.nih.gov/pubmed/16310138
    [73]
    Zhao FH, Forman MR, Belinson J, et al. Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China[J]. Int J Cancer, 2006, 118: 442-448. DOI: 10.1002/ijc.21327
    [74]
    How CD4 Counts Help Treat HIV and AIDS[EB/OL]. (2019-06-23)[2020-11-26]. https://www.webmd.com/hiv-aids/cd4-count-what-does-it-mean.
    [75]
    Denny L, Hendricks B, Gordon C, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study[J]. Vaccine, 2013, 31: 5745-5753. DOI: 10.1016/j.vaccine.2013.09.032
    [76]
    Kojic EM, Kang M, Cespedes MS, et al. Immun-ogenicity and safety of the quadrivalent human papillo-mavirus vaccine in HIV-1-infected women[J]. Clin Infect Dis, 2014, 59: 127-135. DOI: 10.1093/cid/ciu238
    [77]
    McClymont E, Lee M, Raboud J, et al. The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus[J]. Clin Infect Dis, 2019, 68: 788-794. DOI: 10.1093/cid/ciy575
    [78]
    Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study[J]. Ann Rheum Dis, 2013, 72: 659-664. DOI: 10.1136/annrheumdis-2012-201393
    [79]
    Nelson DR, Neu AM, Abraham A, et al. Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD[J]. Clin J Am Soc Nephrol, 2016, 11: 776-784. DOI: 10.2215/CJN.09690915
    [80]
    Praditpornsilpa K, Kingwatanakul P, Deekajorndej T, et al. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD[J]. Nephrol Dial Transplant, 2017, 32: 132-136. http://smartsearch.nstl.gov.cn/paper_detail.html?id=be9b371a7a34532890f084946ddaa72c
    [81]
    Reinholdt K, Thomsen LT, Dehlendorff C, et al. Human papillomavirus-related anogenitalpremalignancies and cancer in renal transplant recipients: A Danish nationwide, registry-based cohort study[J]. Int J Cancer, 2020, 146: 2413-2422. DOI: 10.1002/ijc.32565
    [82]
    Kumar D, Unger ER, Panicker G, et al. Immuno-genicity of quadrivalent human papillomavirus vaccine in organ trans-plant recipients[J]. Am J Transplant, 2013, 13: 2411-2417. DOI: 10.1111/ajt.12329
    [83]
    CIOMS Working Groups. Guidelines for Preparing Core Clinical-Safety Information on Drugs[M/OL]. [2020-11-26]. https://cioms.ch/wp-content/uploads/2018/03/Guidelines-for-Preparing-Core-Clinical-Safety-Info-Drugs-Report-of-CIOMS-Working-Group-Ⅲ-and-Ⅴ.pdf.
    [84]
    Reiter PL, Brewer NT, Gottlieb SL, et al. How much will it hurt? HPV vaccine side effects and influence on completion of the three-dose regimen[J]. Vaccine, 2009, 27: 6840-6844. DOI: 10.1016/j.vaccine.2009.09.016
    [85]
    Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years[J]. Hum Vaccin, 2009, 5: 705-719. DOI: 10.4161/hv.5.10.9518
    [86]
    Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase Ⅲ randomized study of healthy women aged 18-45 years[J]. Hum Vaccin, 2011, 7: 1343-1358. DOI: 10.4161/hv.7.12.18281
    [87]
    Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial[J]. Cancer Med, 2017, 6: 12-25. DOI: 10.1002/cam4.869
    [88]
    Chen W, Zhao Y, Xie X, et al. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up[J]. Vaccine, 2019, 37: 889-897. DOI: 10.1016/j.vaccine.2018.12.030
    [89]
    Moreira ED Jr, Block SL, Ferris D, et al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase Ⅲ Clinical Trials[J]. Pediatrics, 2016, 138: e20154387. DOI: 10.1542/peds.2015-4387
    [90]
    Lu B, Kumar A, Castellsagué X, et al. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis[J]. BMC Infect Dis, 2011, 11: 13. DOI: 10.1186/1471-2334-11-13
    [91]
    Yih WK, Greene SK, Zichittella L, et al. Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females[J]. Vaccine, 2016, 34: 172-178. DOI: 10.1016/j.vaccine.2015.09.087
    [92]
    Centers for Disease Control and Prevertion. HPV Vaccine Safety and Effectiveness Data[EB/OL]. (2019-11-15)[2020-11-26]. https://www.cdc.gov/hpv/hcp/vaccine-safety-data.html.
    • Related Articles

  • Related Articles

    [1]LI Shuting, DONG Lili, YANG Xinlei, LÜ Lin, LIU Fukai. Exploratory Study on the Impact of Intestinal Fungi on the Progression of Heart Failure in Patients with Chronic Kidney Disease[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2025-0016
    [2]TIAN Kunling, CHEN Chuanning. Notch Signaling Pathway and Congenital Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 649-654. DOI: 10.12290/xhyxzz.2023-0594
    [3]XU Fen, ZHOU Zhou. Heart Failure: Prevention and Treatment are Indispensable[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 953-957. DOI: 10.12290/xhyxzz.2022-0440
    [4]QIU Luhong, LIU Yingxian, XU Xiqi. Nonnegligible Myocarditis: Insights from 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 530-534. DOI: 10.12290/xhyxzz.2022-0077
    [5]XU Fen, ZHOU Zhou. Universal Definition and Classification of Heart Failure Triggers the Standardization of Diagnosis and Treatment of Heart Failure[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(5): 621-623. DOI: 10.12290/xhyxzz.2021-0436
    [6]QIN Yongwen, BAI Yuan. History and Development of Interventional Devices forCongenital Heart Diseases in China[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 309-312. DOI: 10.12290/xhyxzz.2021-0148
    [7]XIAO Jiawang, ZHU Xianyang. Evolution of Interventional Treatment of Congenital Heart Disease in China[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 303-308. DOI: 10.12290/xhyxzz.2021-0157
    [8]AI Shanshan, HE Aibin. Advances in Basic Research of Congenital Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 291-297. DOI: 10.12290/xhyxzz.2021-0055
    [9]ZHANG Hao, LI Shoujun, SU Zhanhao. Reflections on Improving the Diagnosis and Treatment of Congenital Heart Diseasein China: the Regionalization of Care for Congenital Heart Surgery[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 287-290. DOI: 10.12290/xhyxzz.20200280
    [10]Shuai HU, Zhi-yan HAN, Xiao-jian WANG, Jing-jun HAN, De-qiang WU, Lei ZHANG, Yan-gui LIN, Jian-wen LIANG, Wen-bin WEI, Wen-lin ZHANG, Cun-fu MU, Yi WANG, Dian-yuan LI. Monitoring Value of Central Venous Oxygen Saturation, the Substitute for Mixed Venous Oxygen Saturation, in Postoperative Care of Congenital Heart Disease with Pulmonary Arterial Hypertension:a Multicenter Prospective Study[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 228-233. DOI: 10.3969/j.issn.1674-9081.2018.03.008

  • Cited by

    Periodical cited type(5)

    1. 张东梅，黄玉葵，郑文金，詹凤丽，曾文振，周利锴. 南宁市围绝经期女性对围绝经期知识认知的现状调查. 中国妇幼保健. 2024(10): 1825-1828 .
    2. 史碧容，杨道秀，张辉，崔菊远，姚望，吴晓霞，廖小琴，杨长琼，孙晓莺. 恩施市基层医务人员对绝经及其治疗的认知现况调查与分析. 全科医学临床与教育. 2022(06): 552-554 .
    3. 丁鲡，谢莉玲，王富兰，周勤，孙文静. 临床护士围绝经期综合征风险预测模型的构建及验证. 护理研究. 2022(16): 2860-2866 .
    4. 丁鲡，谢莉玲，周勤. 不同等级医院护士围绝经期综合征现状调查及影响因素分析. 护理学杂志. 2022(20): 76-80 .
    5. 李阳美，陈怡帆，戴安琪，王佳茜，王春媛，李欣悦，曾婷婷，徐驰宇，黄娟，奚鑫，邹密，范尧，俞丽丽，周明芳，雷迅. 更年期“一日门诊”持续性综合管理参与者的真实体验研究. 全科护理. 2022(35): 5011-5014 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2813) PDF downloads (752) Cited by(6)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close